UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

November 18, 2026
Date of Report (Date of earliest event reported)

CalciMedica, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-39538**	**45-2120079**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

505 Coast Boulevard South, Suite 300-9 **La Jolla, California**	**92037**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (858) 952-5500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CALC	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c)

As previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 16, 2026, Stephen Bardin resigned as the Chief Financial Officer, principal financial officer and principal accounting officer of CalciMedica, Inc., a Delaware corporation (the "Company"), effective following the filing of the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 (the "Effective Date"). On November 18, 2026, the board of directors of the Company (the "Board") appointed A. Rachel Leheny, Ph.D., the Company's Chief Executive Officer, as the Company's principal financial officer, and Sean Lawler, the Company's Vice President, Finance, as the Company's Chief Accounting Officer and principal accounting officer, in each case effective as of the Effective Date.

Mr. Lawler, age 61, has served as the Company's Vice President, Finance, since June 2023 and previously served as the Company's Controller from September 2020 to June 2023. Prior to joining the Company, Mr. Lawler served as Controller at Immunic Therapeutics from December 2018 to September 2020. Mr. Lawler holds a Bachelor of Science in Finance with a minor in Economics from San Diego State University and is a certified public accountant.

There are no other arrangements or understandings between Mr. Lawler and the Company or any other persons pursuant to which Mr. Lawler was selected as Chief Accounting Officer and principal accounting officer of the Company. There are no related-party transactions between the Company and Mr. Lawler or any of his immediate family members requiring disclosure under Item 404(a) of Regulation S-K. Mr. Lawler does not have any family relationships with any of the Company's directors or executive officers.

Dr. Leheny's biographical information and the terms of her executive compensation arrangements were previously disclosed in the Company's definitive proxy statement on Schedule 14A filed with the SEC on July 23, 2026, and are incorporated herein by reference.

(e)

In connection with Mr. Lawler's appointment, the Board granted Mr. Lawler a stock option to purchase 10,000 shares of the Company's common stock pursuant to the Company's 2023 Equity Incentive Plan (the "2023 Plan"). The option has an exercise price equal to the closing price of the Company's common stock on the Nasdaq Capital Market on the grant date. One forty-eighth of the shares subject to the option vests monthly on the same day of the month as the September 24, 2026 vesting commencement date (or, if there is no corresponding day, on the last day of the month), subject to Mr. Lawler's continuous service through each applicable vesting date. The option is subject to the terms of the 2023 Plan and the applicable stock option agreement.

In connection with his employment with the Company, the Company entered into an offer letter with Mr. Lawler dated October 29, 2020, as amended by an addendum dated December 28, 2020 and an amendment dated March 20, 2025 (as amended, the "Offer Letter"), which sets forth the terms of Mr. Lawler's employment. Mr. Lawler's current annual base salary is $270,400. Pursuant to the Offer Letter, Mr. Lawler is also eligible to receive an annual performance bonus with a target equal to 30% of his base salary for the prior fiscal year, based on the achievement of individual and Company performance objectives established by the Board and subject to the Board's discretion and his continued employment through the payment date.

Under the terms of the Offer Letter, if Mr. Lawler's employment is terminated by the Company without cause or by Mr. Lawler for good reason, and subject to his continued compliance with his obligations to the Company, resignation from any other positions or roles held with or on behalf of the Company, and delivery of an executed release of claims in favor of the Company, its affiliates and their respective officers and directors within 60 days following termination that becomes fully effective in accordance with its terms, he is entitled to receive (i) six months of salary continuation payments, payable in accordance with the Company's customary payroll schedule beginning on the first payroll date that is at least three business days after these conditions have been satisfied and continuing over the following six months, and (ii) reimbursement of COBRA premiums for Mr. Lawler and his dependents, subject to his timely and proper election of coverage and submission of documentation of premium payments within 60 days after payment, until the earliest of six months following termination, the date he is no longer eligible for COBRA coverage and the

date he becomes eligible for substantially similar coverage from another employer or other source. If the Company determines that COBRA reimbursement would violate applicable law or is otherwise impracticable, it will instead make equivalent taxable monthly cash payments for the remainder of the applicable reimbursement period. Such severance benefits may not be aggregated with any other severance benefits made available by the Company pursuant to any written agreement, plan or policy. The Offer Letter also contemplates Mr. Lawler's participation in the Company's Change in Control Severance Policy (the "Severance Policy"), subject to its eligibility requirements, a copy of which is filed as Exhibit 10.11 to the Company's Registration Statement on Form S-1, filed with the SEC on September 4, 2020. If Mr. Lawler's employment terminates in connection with a change in control and he is eligible for severance under the Severance Policy, his severance rights will be governed exclusively by the Severance Policy and not by the severance provisions of the Offer Letter.

The foregoing summary of the Offer Letter is not complete and is qualified in its entirety by reference to the full agreement, a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2026.

The Company and Mr. Lawler have also entered into the Company's standard indemnification agreement for the Company's directors and officers, a copy of which is filed as Exhibit 10.1 to the Company's Registration Statement on Form S-1, filed with the SEC on September 4, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CALCIMEDICA, INC.

Date: November 24, 2026

By: */s/ A. Rachel Leheny*

A. Rachel Leheny, Ph.D.

Chief Executive Officer (*Principal Executive Officer and Principal Financial Officer*)